Marvin C. Gershengorn, M.D.

Senior Investigator

Laboratory of Endocrinology and Receptor Biology

NIDDK

Building 50, Room 4134
50 South Dr
Bethesda, MD 20814

+1 301 451 6305

marvin.gershengorn@nih.gov

Research Topics

To discover and develop probes or drugs for receptors for thyroid-stimulating hormone (TSH) and thyrotropin-releasing hormone (TRH).

Current Research

I conduct studies on the structure-function relationships of G protein-coupled receptors—in particular, receptors for thyrotropin-releasing hormone (TRH) and thyroid-stimulating hormone (TSH). An important aspect of this research is to discover small molecule ligands for these receptors that can be used as probes in animal models and that can lead to the development of drugs for the treatment of endocrine and neurologic diseases in humans.

Applying our Research

This research may allow us to discover and develop drugs to treat several diseases of the thyroid gland including thyroid cancer, Graves’ hyperthyroidism, and ophthalmopathy. It will also allow us to discover and develop drugs to treat several neurologic diseases including narcolepsy, depression, and cancer-related fatigue.

Need for Further Study

Small molecule drug-like ligands for these receptors are not available.

Biography

  • Abby Rockefeller Mauzé Distinguished Professor of Endocrinology in Medicine, Cornell University Medical College, 1983–2001
  • Chief of the Division of Endocrinology and Metabolism, Cornell University Medical College, 1983–2001
  • Professor of Medicine and Cell Biology and Genetics, Cornell University Medical College, 1983–2001
  • Assistant and Associate Professor, New York University School of Medicine, 1976–1983
  • M.D., New York University School of Medicine, 1971
  • B.S., City College of the City University of New York, 1967

Selected Publications

  1. Krieger CC, Boutin A, Jang D, Morgan SJ, Banga JP, Kahaly GJ, Klubo-Gwiezdzinska J, Neumann S, Gershengorn MC. Arrestin-β-1 Physically Scaffolds TSH and IGF1 Receptors to Enable Crosstalk. Endocrinology. 2019;160(6):1468-1479.

  2. Neumann S, Eliseeva E, Boutin A, Barnaeva E, Ferrer M, Southall N, Kim D, Hu X, Morgan SJ, Marugan JJ, Gershengorn MC. Discovery of a Positive Allosteric Modulator of the Thyrotropin Receptor: Potentiation of Thyrotropin-Mediated Preosteoblast Differentiation In Vitro. J Pharmacol Exp Ther. 2018;364(1):38-45.

  3. Marcus-Samuels B, Krieger CC, Boutin A, Kahaly GJ, Neumann S, Gershengorn MC. Evidence That Graves' Ophthalmopathy Immunoglobulins Do Not Directly Activate IGF-1 Receptors. Thyroid. 2018;28(5):650-655.

  4. Dougherty JP, Wolff BS, Cullen MJ, Saligan LN, Gershengorn MC. Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue. Pharmacol Res. 2017;124:1-8.

  5. Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC. TSH/IGF-1 Receptor Cross Talk in Graves' Ophthalmopathy Pathogenesis. J Clin Endocrinol Metab. 2016;101(6):2340-7.


This page was last updated on October 25th, 2019